RxDoctor Payments DataLook up a doctor →

Matthew Martinez, MD

Cardiovascular Disease · Allentown, PANPI 1770556243

Payments from drug & device makers

$663,897in general payments, 2019–2025

Across 534 payments — averaging $1243.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$616K
  • Novartis$41K
  • Irhythm Technologies, Inc.$3K
  • Sanofi$1K
  • Pfizer$393
  • Amgen$325
  • plus $2K from 21 others

What the payments were for

  • Consulting fees$83,27520%
  • Speaking & faculty fees$284,33268%
  • Travel & lodging$41,47810%
  • Food & beverage$9,6322%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$663,897 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$93,200
Medicare patients
269
Services billed
865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten354$2,869,816
EliquisApixaban55$73,866
JardianceEmpagliflozin58$64,427
EntrestoSacubitril/Valsartan45$56,294
FarxigaDapagliflozin Propanediol41$45,776
Verapamil ErVerapamil Hcl73$2,578
Metoprolol Succinate106$1,442
Valsartan13$640
Losartan Potassium40$555
Spironolactone31$457
Rosuvastatin Calcium12$323
Atorvastatin Calcium28$241
Metoprolol Tartrate17$134
Amoxicillin65$61

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$616,135$2,869,816354 claims
PfizerEliquis$393$73,86655 claims
Boehringer IngelheimJardiance$325$64,42758 claims
NovartisEntresto$41,039$56,29445 claims
AstraZenecaFarxiga$120$45,77641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →